ArticleEndocrine2026
The impact of RET fusions on radioiodine avidity and prognosis in patients with distant metastatic papillary thyroid cancer.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRET gene fusion is one of the key oncogenic drivers in papillary thyroid cancer (PTC). However, the impact of different RET fusion subtypes on clinicopathological features and radioiodine (RAI) avidity in metastatic PTC remains unclear.
methodsWe retrospectively analyzed clinicopathological data, RAI avidity, and progression-free survival (PFS) in RET-driven metastatic PTC. Initial RAI avidity status was classified as initially RAI-avid (all or partial lesions showing uptake in the first therapy) or initially RAI-non-avid (all lesions with no uptake in the first therapy). The definition of RAI refractory (RAIR) was based on the 2025 ATA guidelines.
resultsAmong 65 enrolled patients, 25 (38.5%) harbored CCDC6-RET, 24 (36.9%) NCOA4-RET, and 16 (24.6%) other RET fusions. Older age was associated with the other RET fusion group (P = 0.011). NCOA4-RET patients were more likely to be initially RAI-avid (P = 0.017). Overall, 46.8% (29/62) of evaluable patients were classified as RAIR (CCDC6: 56.0%, NCOA4: 27.3%, other RET fusions: 60.0%; P = 0.072). TERT promoter mutation (18.2%, 8/44) in RET-fusion PTC was associated with older age (P < 0.001), larger metastatic lesions (P = 0.012) and metastatic sites beyond lungs (P = 0.002). RAIA patients demonstrated a longer median PFS compared with RAIR patients (86 vs. 33 months), but this association was not statistically significant (P = 0.402).
conclusionIn this metastatic RET-driven PTC cohort, 46.8% of evaluable patients eventually develop RAIR status. While the specific RET subtypes are associated with initial RAI avidity status, no significant differences in RAIR status or PFS were observed across distinct RET subtypes, warranting further exploration in larger sample sizes.
Indexed as
Identifiers
42804115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.